News

Artificial intelligence expert enhances cancer diagnostic testing & delivers value to your NGS Data!

Published on: 07/07/2021

Artificial intelligence expert enhances cancer diagnostic testing & delivers value to your NGS Data!
AI, Cancer
Member News

Find out about our novel approach to cancer diagnosis. We’ll present our very high accuracy and show how many lives can be saved if cancer is detected early. Although not covered in this article, our platform can help develop other analyses as well, e.g., AI platform for NGS data analysis.

Every year, cancer claims the lives of over 8 million people. To fight this epidemic, the World Health Organization is encouraging governments to focus on early, non-invasive detection, which has been shown to dramatically increase treatment success. Unfortunately, current diagnostic testing and screening tools lack the necessary accuracy rates, meaning many patients remain undiagnosed.

To enable early diagnoses and screening for a wide array of cancer types, Romanian start-up company Artificial Intelligence Expert (AIE), with support from the EU, developed an extremely accurate diagnostic tool. Called AI-MICADIS, the solution uses circulating microRNAs instead of the more commonly used circulating tumour DNA and circulating cancer cells. It also uses innovative deep learning artificial intelligence (AI) algorithms to provide real-time analysis of polymerase chain reaction (PCR), microarray, and next generation sequencing (NGS) data – all essential factors in detecting the earliest stages of cancer progression.

“By selecting informative molecular alterations and using artificial intelligence, we developed the best non-invasive multi-cancer diagnosis and early detection tests available,” says Alexandru Floares, an AIE researcher and coordinator of the EU-funded AI-MICADIS project.

During the AI-MICADIS project, AIE conducted a feasibility study to test the tool, identify potential partners, set out a regulatory path, and optimise the best strategy for bringing AI-MICADIS to market.

Near perfect accuracy

As to the feasibility of the AI-MICADIS tool itself, the project tested it on 6 000 patients. From this work, researchers were able to extend its use from nine to thirteen cancer types. They also added new AI methods capable of learning from only a few cases – an advancement that enables faster and less costly validation of the tests.

Originally, the AI-MICADIS tool was configured to discriminate between cancer and normal cells. But after testing the tool with oncologists, researchers learned there was more interest in discriminating between cancer and benign diseases. Unfortunately, this capability was not possible with the system’s current molecular set-up. In fact, when it came to distinguishing the malignant from the benign, AI only achieved 67 % accuracy – a far cry from the near perfect diagnosis rates the team was hoping for.

Instead of throwing in the towel, the AIE team went back to the drawing board to reframe the problem and develop new techniques. “In the end, we proved a remarkable 99 % accuracy rate, along with the tool’s ability to discriminate between malignant and benign diseases,” explains Floares. “Furthermore, we demonstrated that the use of data science and AI to integrate multiple studies outperformed the use of a single extensive study in terms of costs, efficiency and results.”

A solid business case

As to the business case for AI-MICADIS, Floares notes that the project allowed his team to learn more about their potential customers and to better understand the complex regulatory environments of both the EU and United States. “We made our team stronger on the business side and we identified potential partners. We also won other project competitions and identified potential investors, which puts us in a good position to move towards marketisation,” Floares says.

AIE is currently working to secure the funding needed to bring the AI-MICADIS tool to the global market, while also adding new cancer types to the system’s portfolio.

Keywords

AI-MICADIS, artificial intelligence, AI, cancer, World Health Organization, WHO, diagnostic testing, deep learning

Discover More

AI-MICADIS is using AI and Digital Automation to create the most performant non-invasive molecular and imaging intelligent systems for early diagnosis and personalised treatment of patients, e.g., we are making early cancer diagnosis a routine.

NEWS​

Related News

HLTH Brought the Energy to Amsterdam. Now It’s Vegas’ Turn.

26 Jun 2025
Next up: HLTH USA, October 19–22 in Las Vegas.

From Abandonment to Belonging: Hands 4Life’s Vision for Generational Healing

26 Jun 2025
Hands 4Life is a nonprofit organization addressing the global aging crisis by empowering communities in economically developing nations—beginning with...

Strengthening Elderly Care Innovation Across Europe: ECHAlliance at the NOTRE Project Meeting in Lille

26 Jun 2025
ECHAlliance participated in the latest partner meeting of the NOTRE Project, hosted in Lille, France by our Hauts-de-France ecosystem led by Eurasanté...

Africa Health Business Co-founder Dr Amit Thakker Honoured with Top Civilian Award

26 Jun 2025
Dr. Amit N. Thakker, Co-founder of our partner Africa Health Business, receives one of the highest civilian awards from the President of Kenya.

Highlights from the Global Health Connector Partners Programme at HLTH Europe 2025

25 Jun 2025
Our Global Health Connector Partners Programme returned to HLTH Europe this June with an energising series of sessions, conversations and connections ...

That’s a Wrap from HIMSS Europe 2025!

24 Jun 2025
From Paris with purpose: Gnomon Informatics SA returned to HIMSS Europe for a third year of bold ideas, smart tech, and stronger-than-ever momentum in...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *